drugset / Trial / NCT00308737

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737

Phase 3 Completed 2053 enrolled Mannkind Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

Pulmonary Safety in Diabetics with T/I

Timeline

Start
2005-06
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 15 iu Inhaled
Subject Insulin Protein / enzyme biologic 30 iu Inhaled